You're*
Learn to spell, dumbass
I'm not decrepit like you
Never been prescribed drugs, unlike you
You suck
mfjoss
@mfjoss
·
2h
Replying to @DavidVance
This is sickening
https://www.investopedia.com/top-moderna-sha…
https://www.rollingstone.com/pro/news/who-re…
Baillie Gifford (11.8 percent) Spotify
Baillie Gifford 11.2% of total shares Moderna
https://gettr.com/comment/cmwnfi82d3
Top Moderna Shareholders
By Matthew Johnston
Published April 14, 2021
Moderna Inc. (MRNA) is a biotechnology company that develops medicines based on messenger ribonucleic acid (mRNA), which transfers genetic information to the cellular machinery that makes proteins to sustain life. The company develops medicines for infectious diseases, immuno-oncology, cardiovascular diseases, and other diseases. Its revenue and market value have skyrocketed during the past few quarters after winning Emergency Use Authorization (EUA) for the vaccine it developed to protect against COVID-19.1
The top shareholders of Moderna are Robert S. Langer, Stéphane Bancel, Noubar B. Afeyan, Baillie Gifford & Company, and Flagship Pioneering Inc.
In mid-March 2021, Moderna began testing its COVID-19 vaccine in children aged 6 months to 11 years in the U.S. and Canada. Currently, the company's vaccine is authorized for use in adults aged 18 and older.2
Moderna's 12-month trailing net income and revenue are -$747.1 million and $803.4 million, respectively. The company's market cap is about $59.4 billion. These financial data are as of April 13, 2021.3
"Insider" refers to people in senior management positions and members of the board of directors, as well as people or entities that own more than 10% of the company's stock. In this context, it has nothing to do with insider trading.
Top 3 Individual Insider Shareholders
The shares owned by individual insider shareholders are those that are held through direct ownership. Shares mentioned in this section do not include shares held indirectly nor shares accessible through stock options. Company insiders must file an SEC Form 4 every time they buy or sell an amount of the company's stock that is deemed to be material.
Robert S. Langer
Robert S. Langer owns a total of 11.5 million Moderna shares, representing 2.9% of the company's total shares outstanding.4 Langer serves on the board of directors. He is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) and has about 800 issued and pending patents. He also served as a member of the U.S. Food and Drug Administration's SCIENCE Board between 1995 and 2002, and as its chair from 1999 to 2002. He has won numerous awards, including the Charles Stark Draper Prize, which is considered one of the most prestigious awards in the field of engineering.5 Langer has a net worth of $1.9 billion.6
Stéphane Bancel
Stéphane Bancel owns a total of 6.4 million Moderna shares, representing 1.6% of the company's total shares outstanding.4 Bancel currently serves as chief executive officer (CEO) and as a member of the board of directors. Since joining Moderna in 2011, he has led the company's expansion, partly by raising close to $2 billion through equity financing and licensing collaborations. Before Moderna, Bancel was CEO of bioMérieux SA, a French-based biotechnology company. Prior to that, he worked in numerous roles at drugmaker Eli Lilly & Co. (LLY).5 Bancel has a net worth of $4.9 billion.7
Noubar B. Afeyan
Noubar B. Afeyan owns a total of 2.1 million Moderna shares, representing 0.5% of the company's total shares outstanding.4 Afeyan is one of the company's co-founders and is chair of the board. He is also the founder and CEO of Flagship Pioneering Inc., a venture capital firm that invests in the pharmaceutical, electronic, and medical devices sectors. He has co-founded and helped to build more than 40 life science and technology startups and serves on the boards of several Flagship companies as well as Moderna.5 Afeyan has a net worth of $2.1 billion.8
Top 3 Institutional Shareholders
Institutional investors hold between 43-51% of Moderna's total shares outstanding.910 Institutional investors institutional investment managers with at least $100 million in assets under management (AUM) must file an SEC Form 13F every quarter to disclose their equity holdings. Individual investors may be considered institutional investors if they acquire 5% or more of a company's shares, thus requiring them to file either a Schedule 13D or Schedule 13G form.
Baillie Gifford & Co.
Baillie Gifford owns 44.7 million shares of Moderna, representing 11.2% of total shares outstanding, according to the company's 13G filing for the period ending Feb. 1, 2021.11 The U.K.-based company is a global investment management firm that provides portfolio management, consulting, financial planning, and investment supervisory services. Baillie Gifford has $445.3 billion in AUM and manages a range of mutual funds.1213 Moderna is among the top ten holdings of the firm's Baillie Gifford Positive Change Equities Fund, comprising about 5.5% of the portfolio.14
Flagship Pioneering Inc.
Flagship Pioneering owns 30.9 million shares of Moderna, representing 7.7% of total shares outstanding, according to the company's 13F filing for the period ending Dec. 31, 2020.11 As mentioned above, Flagship is a venture capital firm. Its team of experienced scientists, entrepreneurs, and operational executives seeks to identify and invest in early-stage and growth-stage companies that could benefit from economies of scale.15 In the company's last reported 13F filling, it held $5.5 billion in managed 13F securities. Moderna was its largest holding, comprising 58.7% of its portfolio.16
Stéphane Bancel
Stéphane Bancel, as an institutional investor, owns 28.7 million shares of Moderna, representing 7.2% of total shares outstanding, according to his 13G filing for the period ending Dec. 31, 2020.11 Bancel's institutional holdings include shares of which he has direct ownership, as noted in the individual insider section above. According to his 13G, Bancel has direct ownership of about 6.5 million shares of Moderna, slightly above the figure mentioned earlier. The difference can be explained by the difference in timing between his most recent 13G filing and Form 4 filing. Form 4's are usually more recent since they must be filed whenever a material amount of shares are either bought or sold. Bancel's institutional holdings also include shares of Moderna that are held indirectly through OCHA LLC and Boston Biotech Ventures LLC, both of which Bancel is the majority unit holder and sole managing member. OCHA directly owns 7.6 million Moderna shares while Boston Biotech owns about 9.1 million shares. Additionally, Bancel's institutional holdings include 5.2 million shares issuable upon exercise of share options and approximately 0.2 million shares held by a trust for the benefit of his family. Because Bancel is in a position where he has sole voting power over these 28.7 million shares, regardless of whether they are held indirectly or not, he is required to disclose these holdings. The SEC requires high levels of disclosure and transparency as it aims to protect the integrity of capital markets for the benefit of all investors.17
https://www.investopedia.com/top-moderna-shareholders-5176519
The TOP Owner of Spotify Is Also The Top Owner of Moderna!
https://www.youtube.com/watch?v=7QVyQzzlf-U
Checks out, Baillie Gifford & Co. Highest shareholder of both Moderna and Spotify.
"The Top Owner of Spotify Is Also The Top Owner of Moderna"
https://gettr.com/post/ptoayef234
Zero Rekt
@Z3r0An0n
· 17h
Just found this;
Baillie Gifford & Co. Partners of Vanguard.
Working on ESG (social credit score)
https://prnewswire.com/news-releases/vanguard-to-expand-esg-lineup-with-positive-impact-stock-fund-301463935.html
Show this thread
https://twitter.com/Z3r0An0n/status/1491700741362237442
Vanguard to Expand ESG Lineup with Positive Impact Stock Fund
VALLEY FORGE, Pa., Jan. 19, 2022 /PRNewswire/ – Vanguard today filed an initial registration statement with the U.S. Securities and Exchange Commission to introduce Vanguard Baillie Gifford Global Positive Impact Stock Fund, which is designed to meet the needs of investors seeking actively managed global equity returns along with measurable impact on environmental and social challenges. The fund is expected to launch in the second quarter of 2022 and subsequently seek to adopt the existing Baillie Gifford Positive Change Equities Fund, contingent upon shareholder approval. Vanguard expects to make the combined fund available for public investment in the third quarter.
"We'll continue to thoughtfully expand our ESG lineup, introducing funds and ETFs with enduring investment merit that reflect clients' needs and preferences," said Vanguard Chairman and CEO Tim Buckley. "The new Global Positive Impact Stock Fund will tap Baillie Gifford's significant expertise in fundamental equity research and impact analysis, helping our clients to achieve both their impact and investment goals."
Impact investing is a dual-mandate investment strategy in which portfolio managers target companies that will generate returns as well as positive social and/or environmental impact. Vanguard believes an active approach to impact investing enables skilled managers to better navigate the complexities of identifying companies driving positive change and build a portfolio with the potential to deliver on both excess return and impact objectives.
Vanguard's new fund will seek to adopt the existingBaillie GiffordPositive Change Equities Fund. Introduced in 2017, Baillie Gifford's fund employs a consistent framework to identify high-quality growth companies driving solutions to global challenges. Its portfolio managers expect these companies to achieve strong long-term returns. The fund's global mandate provides clients with the broadest exposure to companies that meet both excess return and impact objectives.
In the second quarter of 2022,Baillie Giffordwill conduct a proxy vote for approval from the Positive Change Equities Fund's existing shareholders to undergo a tax-free reorganization into the new Vanguard fund. Vanguard and Baillie Gifford are confident that this approach serves both existing and prospective investors, as the new fund is expected to have lower shareholder costs. If the reorganization is approved, current shareholders of the Positive Change Equities Fund are expected to realize an expense ratio reduction of approximately 0.06%. With an estimated expense ratio of 0.59%, the new Vanguard fund will be favorably priced compared to similar funds in its category, which have an average expense ratio of 1.49%.1
Vanguard Baillie Gifford GlobalPositive Impact Stock Fund will maintain the investment objectives and portfolio management team of the existing Baillie Gifford fund, ensuring consistency upon reorganization. Furthermore, Baillie Gifford will continue to produce an annual impact report using robust, bottom-up research that complements its investment analysis.
"We hope that this fund adoption will broaden access to impact investing at a very competitive cost," said Andrew Telfer, Baillie Gifford Joint Senior Partner. "As a result, it should help to channel more capital towards companies driving positive change."
A growing ESG lineup
Vanguard has offered ESG funds to U.S. investors for more than two decades and continues to broaden its lineup with solutions that enable investors to better align investment objectives with personal values and ESG considerations. Vanguard has grown its ESG lineup to reflect the evolving investment goals of investors. Vanguard's exclusionary-screened equity and fixed income ETFs serve investors who want to reflect certain values or prefer to avoid certain sectors or ESG risks in their portfolio. The firm's existing active ESG mutual fund is designed for clients who want to invest in companies with leading ESG practices and strong business fundamentals. The new Global Positive Impact Stock Fund will broaden Vanguard's overall ESG product suite and expand the firm's active ESG offerings.
About Vanguard
Vanguard is one of the world's largest investment management companies. As of November 30, 2021, Vanguard managed $8.2 trillion in global assets. The firm, headquartered in Valley Forge, Pennsylvania, offers 421 funds to its more than 30 million investors worldwide. For more information, visit vanguard.com.
About Baillie Gifford
Baillie Gifford is an independent investment partnership founded in Edinburgh in 1908, focused on long-term growth investing in some of the world's most exciting companies. With 1,576 staff and assets under management of $468 billion, it has offices in Edinburgh (HQ), Dublin, Frankfurt, Hong Kong, Krakow, London, New York, Shanghai, Toronto and Zurich. Baillie Gifford has worked with Vanguard since 2003 and manages $69 billion of assets on behalf of the Pennsylvania-based firm.
Asset figures as of November 30, 2021, unless otherwise noted.
1 Sources: Morningstar, Vanguard.
Registration statements relating to Vanguard Baillie Gifford Global Positive Impact Stock Fund have been filed with the Securities and Exchange Commission (SEC) but have not yet become effective. The SEC has not approved or disapproved these securities or passed upon the adequacy of either fund's preliminary prospectus. Any representation to the contrary is considered a criminal offense. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statements become effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Where to find additional information
In connection with the proposed reorganization, a definitive proxy statement/prospectus will be filed with the SEC. All shareholders are advised to read the definitive proxy statement/ prospectus in its entirety when it becomes available, because it will contain important information regarding the fund, the reorganization, the board's considerations in recommending the reorganization, the persons soliciting proxies in connection with the reorganization and the interest of these persons in the reorganization and related matters.
https://www.prnewswire.com/news-releases/vanguard-to-expand-esg-lineup-with-positive-impact-stock-fund-301463935.html
BOOM
>>15598985, >>15598996, >>15598998, >>15599011, >>15599017, >>15599034, >>15599035, >>15599049, >>15599059, >>15599063, >>15599123 Baillie Gifford & Co. Highest shareholder of both Moderna and Spotify
connections Andrew Telfer, Ian Telfer, Chairman of Uranium One?
I apologie about missing ZOT
fuck off
dead link